MedTrace Logo

Cartesia eXTend 3D Study

NCT04577651 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-02-21

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the treatment of Parkinson's Disease (PD).

Conditions

  • Parkinson Disease

Interventions

DEVICE

16-contact Directional Deep Brain Stimulation

Deep Brain Stimulation with 16-contact Directional Lead

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Natalie Bloom Lyons · Boston Scientific Neuromodulation Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2023-02-27
Completion
2025-01-28
FDA Device
Yes

Countries

  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577651 on ClinicalTrials.gov